Thymosin alpha-1: an immune peptide and what the studies showed
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Thymosin alpha-1: an immune peptide and what the studies showed

Thymosin alpha-1 (thymalfasin): how the immune peptide works, what studies showed in hepatitis B and C, sepsis, vaccination, melanoma and COVID-19, and how it is used.

Thymosin alpha-1: an immune peptide and what the studies showed
Thymosin alpha-1 is an immune peptide of 28 amino acids. How it works, what studies showed in hepatitis, sepsis, vaccination and COVID-19, the regimens, and who should see a doctor first.

The main point

Thymosin alpha-1 (thymalfasin) is a synthetic peptide of 28 amino acids that copies a substance first isolated from the thymus gland. According to a review, the drug (Zadaxin) is registered in more than 35 countries for hepatitis B and C and as an agent that supports immunity (Dominari A World J Virol 2020. PMID 33362999). Its strengths are clear: the mechanism is described in reviews, in short courses the number of adverse events did not differ from placebo, and the most noticeable results came in hepatitis, combined with other drugs. In sepsis, the largest double-blind study showed no difference between the groups. Below, for each condition, you will find the study figures, the regimens and the cases when a doctor is needed first. A related topic: Cordyceps and immunity: what the Das et al., 2021 review showed.

Substance and formWhat it doesWhat the studies showedWho it is discussed for
Thymosin alpha-1, subcutaneous injections, in hepatitis Bsends a signal to immune system cells10 studies, 1349 people: mortality results are mixed, certainty is very lowadults with chronic hepatitis B
Thymosin alpha-1 with interferon, in hepatitis Cwas added to interferon in a study109 people, 1 study: biochemical response at the end of the course 37.1% versus 16.2%adults with chronic hepatitis C
Thymosin alpha-1 in sepsisstudied as a signal to immune cells in severe infection1089 people, 1 study: 28-day mortality 23.4% versus 24.1%, no differenceadults in intensive care, in studies
Thymosin alpha-1 with a vaccineantibody titers were higher in studies94 people on dialysis, pilot: antibody titers higher on day 21older people and people on dialysis
Thymosin alpha-1 with chemotherapywas added to chemotherapy in a study488 people, 1 study: tumor responses 10 and 12 versus 4, no significant difference in survivaladults with metastatic melanoma
Thymosin alpha-1 in COVID-19T-cell counts were followed in studiesafter matching, no clinical benefit was shownhospitalized adults, in studies

How it works

The thymus is a gland behind the breastbone where T cells mature, the main “coordinators” of immunity. Thymosin alpha-1 acts as a signal: according to reviews, it switches on Toll-like receptors (TLR9 and TLR2) on myeloid and dendritic cells, helps T-cell precursors mature, activates dendritic cells and natural killer cells (NK cells), and increases production of interleukin-2 (Dominari A World J Virol 2020. PMID 33362999; King R Vitam Horm 2016. PMID 27450734). The authors of the review call this action on several types of immune cells pleiotropic.

After administration, immune cell measures changed in clinical studies. In sepsis, in the ETASS study HLA-DR on monocytes (a marker of immune cell activity) was higher: by 3.9% on day 3 (P = 0.037) and by 5.8% on day 7 (P = 0.017); in a meta-analysis of 8 studies (721 people) this measure was also higher (Liu F BMC Infect Dis 2016. PMID 27633969). In the large TESTS study there was no difference in it on day 7 (P = 0.89). In COVID-19, in a pilot study of 49 people, in the low-flow oxygen subgroup, by day 5 there were 3.84 times more CD4 cells than in the control group (P = 0.01). Cell measures do not change in every study, and they do not always translate into outcomes for the person, so the main attention below is on outcomes.

Hepatitis B

Chronic viral hepatitis B is the oldest indication. A Cochrane systematic review (Naing C Cochrane Database Syst Rev 2026. PMID 42713852) pooled 10 randomized studies, 1349 people from six countries, published in 1991–2018. All-cause mortality: risk ratio 0.53 (95% confidence interval, CI, 0.29–0.96; 3 studies, 907 people), certainty very low. Serious adverse events: 0.72 (0.53–0.99; 5 studies, 1056 people), certainty low. Quality of life (1 study, 161 people) and biopsy improvement (2 studies, 702 people) did not differ. The authors word it cautiously: they are not certain that thymosin alpha-1 reduces mortality and serious adverse events. The results in hepatitis B are mixed.

Combinations with other drugs look better. In a meta-analysis of 8 studies (583 people with HBeAg-positive hepatitis B), the combination with lamivudine versus lamivudine alone gave ALT (a liver enzyme) normalization in 80.2% versus 68.8%, a virological response in 84.7% versus 74.9% and HBeAg seroconversion (a switch to HBeAg-negative) in 45.1% versus 15.2% (Zhang YY Virol J 2009. PMID 19467157). A pharmacology review (Ancell CD Am J Health Syst Pharm 2001. PMID 11381492) describes a randomized study in which viral DNA disappeared in 40.6% after 6 months and in 25.6% after 12 months versus 9.4% in the control group.

In comparison with interferon (a meta-analysis of 4 studies, 199 people), thymosin did not outperform it at the end of the course: odds ratio for a complete response 0.54 (0.30–0.97). 6 months after the end of treatment the picture changed: virological response 3.71 (2.05–6.71), biochemical 3.12 (1.74–5.62), complete 2.69 (1.47–4.91) in favor of thymosin (Yang YF Antiviral Res 2008. PMID 18078676). The authors of the 2020 review note that its use in hepatitis belongs to the interferon era, when modern antiviral drugs did not exist.

Hepatitis C

In a double-blind study of 109 people with biopsy-confirmed hepatitis C, thymosin alpha-1 (1.6 mg twice a week) was given with interferon for 26 weeks. Biochemical response at the end of treatment: 37.1% versus 16.2% on interferon alone and 2.7% on placebo (P = 0.04 for the comparison with interferon). Disappearance of viral RNA: 37.1% versus 18.9%. Sustained biochemical response: 14.2% versus 8.1% (significance is not stated in the abstract) (Sherman KE Hepatology 1998. PMID 9537454). In a pilot study of 41 people, the virological response at the end of the course was higher (P = 0.03), and at 6 months of follow-up there was no difference (Andreone P J Viral Hepat 2004. PMID 14738560). Today hepatitis C is treated with direct-acting antivirals, so these studies describe an earlier era of therapy.

Sepsis

Sepsis is a dangerous reaction of the body to infection in which the immune system loses its way. Thymosin alpha-1 was studied here in intensive care. The largest study, TESTS: double-blind, placebo-controlled, 22 centers, 1106 adults, 1089 included in the analysis. Regimen: 1.6 mg under the skin every 12 hours for 7 days. 28-day mortality: 127 of 542 (23.4%) versus 132 of 547 (24.1%); hazard ratio 0.97 (0.76–1.24; P = 0.82). At 90 days: 31.0% versus 32.4%; 0.95 (0.77–1.17). The figures are from the corrected version of the paper. Adverse events occurred in 66.4% and 67.6% of participants, serious ones in 26.8% and 29.3%: in tolerability the drug did not differ from placebo (Wu J BMJ 2025. PMID 39814420). The study was partly funded by the manufacturer; according to the authors, the sponsor took no part in the design and analysis.

In prespecified subgroups the picture varied: under 60 years the hazard ratio was 1.67 (1.04–2.67), at 60 and older 0.81 (0.61–1.09); with diabetes 0.58 (0.35–0.99), without diabetes 1.16 (0.87–1.53). The authors call this a possible difference in effect between groups; such subgroups describe the picture and do not set a general recommendation.

The earlier ETASS study (361 people, no placebo) gave 28-day mortality of 26.0% versus 35.0% (risk ratio 0.74; 0.54–1.02; P = 0.062); there were no serious adverse events related to the drug (Wu J Crit Care 2013. PMID 23327199). A meta-analysis of 11 studies (967 people on thymosin and 960 in the control group) gave an odds ratio of 0.73 (0.59–0.90) in the overall calculation, but among five higher-quality studies (1568 people) 0.82 (0.65–1.03), and among three multicenter ones 0.86 (0.68–1.08). In the individual data of ETASS and TESTS, 174 of 723 (24.1%) versus 195 of 727 (26.8%) died, hazard ratio 0.88 (0.72–1.08) (Gu B Front Cell Infect Microbiol 2025. PMID 40969554).

Vaccination and immune response

Another area is antibody production after a vaccine. In a pilot study in people on hemodialysis (ITT 94 people), 3.2 or 6.4 mg of thymosin was added to the pandemic influenza H1N1 vaccine. On day 21 the mean antibody titers were higher in the thymosin groups, and the criteria of the European Committee for Medicinal Products (CHMP) were fully met. By day 42 the titers in these groups fell more. There were no adverse events related to thymosin; the authors concluded that thymosin enhanced the immunogenicity of this vaccine and called for studies in larger groups (Carraro G Vaccine 2012. PMID 22178096). Antibodies were measured, not the number of people who fell ill.

Earlier, in a double-blind study, 90 men aged 65–99 received thymosin alpha-1 (900 µg/m², 8 doses) with a trivalent influenza vaccine; no toxicity was observed in any group (Gravenstein S J Am Geriatr Soc 1989. PMID 2642497). In a pilot study of 194 people on hemodialysis who received thymosin for 8 weeks (1.6 mg twice a week) versus no treatment, the interim data are as follows: deaths 3 versus 7, serious COVID-19 complications 5 versus 7; the report gives no statistical analysis (Tuthill CW Int Immunopharmacol 2023. PMID 36881981).

Oncology

Metastatic melanoma: in a study of 488 people, thymosin alpha-1 was added to dacarbazine, with or without interferon. A tumor response was noted in 10 and 12 cases in the 3.2 mg groups versus 4 in the control group. Median overall survival was 9.4 versus 6.6 months; hazard ratio 0.80 (0.63–1.02; P = 0.08), so for this measure the difference did not reach significance. There was no added toxicity (Maio M J Clin Oncol 2010. PMID 20194853).

Liver cancer after surgery (hepatocellular carcinoma on a background of hepatitis B): in a retrospective study of 468 people with matched pairs, thymosin was an independent factor for overall survival (hazard ratio 0.308; 0.175–0.541) and recurrence-free survival (0.381; 0.229–0.633). The groups were not randomized, so this is an observational result (Linye H Medicine 2021. PMID 34011034).

COVID-19

In 2020–2021, thymosin alpha-1 was used in hospitalized patients. In an open pilot randomized study (49 people), clinical recovery did not differ significantly (ratio 1.48; 0.68–3.25 on low-flow oxygen) (Shehadeh F J Infect Dis 2023. PMID 36056913). Large observational studies gave this result: among 771 people in serious condition (propensity matching, 522 people) mortality was 51.0% versus 52.9% (Sun Q Int Immunopharmacol 2021. PMID 33208294); among 1388 people with non-severe disease, progression to severe disease was 2.17% versus 2.71% (Huang C Front Med 2021. PMID 33968969). The crude comparison looked more favorable (41.3% versus 60.6%), but after matching on baseline characteristics there was no difference. Two meta-analyses disagree: for 5352 people (9 studies) the risk ratio was 1.03 (0.60–1.75), for 8 studies 0.59 (0.37–0.93) with marked heterogeneity (Shang W Int Immunopharmacol 2023. PMID 36527881; Soeroto AY Inflammopharmacology 2023. PMID 37845598). On the thyroid after viral infections: The thyroid after a virus: three scenarios.

How it is used

All the regimens below are described in studies and reviews; the drug is prescribed and monitored by a doctor, and self-administration is not intended.

  • Form: lyophilized powder, 1.6 mg per vial, dissolved in 1 mL of sterile water for injection; given under the skin.
  • Hepatitis B and C: 1.6 mg (900 µg/m²) under the skin twice a week, usually for 6–12 months; in the hepatitis C study the course lasted 26 weeks.
  • Sepsis, in studies: 1.6 mg twice a day for 7 days (TESTS) or twice a day for 5 days, then once a day for 2 days (ETASS).
  • Oncology, in studies: 1.6, 3.2 or 6.4 mg; for liver cancer after surgery, a regimen of 1.6 mg twice a week for 12 months is described.
  • Vaccination, in studies: 900 µg/m² twice a week, 8 doses, or 3.2 and 6.4 mg.

After administration the blood peak is reached within 2 hours, the half-life is about 1.5–2 hours, and the concentration returns to baseline within 24 hours. Of the adverse events, local irritation at the injection site is described most often; with interferon, fever, fatigue, body aches, nausea, vomiting and a drop in neutrophils were reported rarely (Ancell CD Am J Health Syst Pharm 2001. PMID 11381492; Dominari A World J Virol 2020. PMID 33362999). Another peptide: MOTS-c, a mitochondrial peptide of exercise and metabolism.

Who should see a doctor first

According to a review, the drug is contraindicated in hypersensitivity to thymosin alpha-1 or its components, and in immunosuppression, including after organ transplantation, unless the benefit outweighs the risk. See a doctor first:

  • with an organ transplant and any suppression of immunity;
  • with an allergy to the components of the drug;
  • in pregnancy and breastfeeding, in children, and if use for longer than 12 months is planned: only a doctor decides;
  • in sepsis, severe infection or viral hepatitis: treatment is determined by a doctor in a hospital or a hepatology center.

A doctor will take into account age, other conditions and current therapy.

What the studies showed

What was studiedWho and how manyResultSource
Sepsis, placebo-controlled1089 people, 1 study28-day mortality 23.4% versus 24.1%; hazard ratio 0.97 (0.76–1.24)Wu J BMJ 2025. PMID 39814420
Sepsis, no placebo361 people, 1 study26.0% versus 35.0%; 0.74 (0.54–1.02)Wu J Crit Care 2013. PMID 23327199
Sepsis, meta-analysis1927 people, 11 studiesoverall 0.73 (0.59–0.90); higher-quality 0.82 (0.65–1.03)Gu B Front Cell Infect Microbiol 2025. PMID 40969554
Hepatitis B, Cochrane review1349 people, 10 studiesmortality 0.53 (0.29–0.96), certainty very lowNaing C Cochrane Database Syst Rev 2026. PMID 42713852
Hepatitis B + lamivudine583 people, 8 studiesHBeAg seroconversion 45.1% versus 15.2%Zhang YY Virol J 2009. PMID 19467157
Hepatitis B, comparison with interferon199 people, 4 studies6 months after the course, complete response 2.69 (1.47–4.91)Yang YF Antiviral Res 2008. PMID 18078676
Hepatitis C + interferon109 people, 1 studybiochemical response 37.1% versus 16.2%Sherman KE Hepatology 1998. PMID 9537454
Hepatitis C, pilot41 people, 1 studyat 6 months of follow-up, sustained response did not differAndreone P J Viral Hepat 2004. PMID 14738560
Melanoma + chemotherapy488 people, 1 studysurvival 9.4 versus 6.6 months; 0.80 (0.63–1.02)Maio M J Clin Oncol 2010. PMID 20194853
Liver cancer after surgery468 people, retrospectiveoverall survival 0.308 (0.175–0.541)Linye H Medicine 2021. PMID 34011034
H1N1 influenza vaccine, dialysis94 people, pilotantibody titers higher on day 21Carraro G Vaccine 2012. PMID 22178096
Dialysis, 8 weeks194 people, pilotdeaths 3 versus 7 (interim, no statistics)Tuthill CW Int Immunopharmacol 2023. PMID 36881981
COVID-19, open randomized trial49 people, 1 studyrecovery 1.48 (0.68–3.25)Shehadeh F J Infect Dis 2023. PMID 36056913
COVID-19, matched pairs522 people, 1 studymortality 51.0% versus 52.9%Sun Q Int Immunopharmacol 2021. PMID 33208294
COVID-19, meta-analysis5352 people, 9 studiesrisk ratio 1.03 (0.60–1.75)Shang W Int Immunopharmacol 2023. PMID 36527881

Summary

Thymosin alpha-1 is a well-studied immune peptide with a mechanism described in reviews, registered in more than 35 countries according to a review, and well tolerated in short courses. The best results came in hepatitis B and C combined with other drugs, and in antibody titers after vaccination in pilot studies. In sepsis and COVID-19, large studies showed no difference between the groups. One more look at immunity: Black cumin: cell protection and immune modulation. The decision about such a drug is made by a doctor; you can discuss its place in your situation at a consultation.

Source: Thymosin alpha-1: an immune peptide and what the studies showed — universum.earth. Dr. Pereligyn.

Come back
Request a call back